2020-Present
2020-NOW

Ushering in a New Era of AI Drug Development
2025
December
Certified as a Family-Friendly Company by the Ministry of Gender Equality and Family, Korea
September
ABSC natural convention-based air circulation system patent registerd
June
Signed a drug development agreement with a U.S. animal pharmaceuticals company
May
Signed a joint service agreement with OCMS Bio for an integrated “One-Shot Screening” platform for ultra-fast antibody drug discovery
March
Official global launch of LM-VS (Language Model Virtual Screening) service based on AI drug discovery language model
Signed a $3.1M drug candidate development agreement with U.S. Pragma Biosciences
Partnered with MSK to co-develop new anti-cancer drug compounds
February
Signed a joint research agreement with PDC*line Pharma for a neoantigen cancer vaccine
January
Obtained Platinum grade certification for eco-friendly green data center at ABS Center
2024
December
Signed a DEEPMATCHER® service provision agreement with RUDACURE
November
Signed 1st service agreement with a US Nasdaq-listed TPD-specialized biotech
September
Signed MOU with Enamine (Ukraine) for compound supply, synthesis, and collaborative AI drug discovery
2023
November
Signed MOU with QIMR Berghofer Medical Research Institute (Australia) for joint drug development and commercialization
September
Completed the AI Bio Supercomputing Center in Dungok, Daejeon
July
Signed MOU with U.S. Metaclipse Therapeutics for joint research on personalized therapeutic cancer vaccines
2022
December
Launched STB CLOUD service in the U.S.
2021
November
Signed MOU with JW Pharmaceutical for innovative drug development
July
Signed strategic MOU with KT to build an AI supercomputing center
Established Syntekabio USA, Inc. (New York)
January
Signed joint research agreement with Hanmi Science for COVID-19 drug repurposing
2020
December
Registered domestic patent for SARS-CoV-2 treatment composition
September
Signed MOU with KIMCo, Naver Business Platform, and AI Center
June
Signed joint research agreement with KRIBB for COVID-19 drug repurposing
Selected by the Ministry of Science and ICT as an excellent case in DNA (Data, Network, AI) innovation companies
2016-2019
2016-2019

Expansion into AI-Based New Drug Development
2019
December
Listed on KOSDAQ
June
Raised KRW 19.7 billion in Series C funding led by Yuhan Corporation, Sehan Venture Capital, and Timewise Investment
April
Registered domestic patent for AI-based new drug development system
March
Licensed-in an immune-oncology drug candidate co-discovered with CJ Healthcare
2018
December
Published a paper on integrated genomic core technology in BMC Bioinformatics 2018
Signed a collaboration agreement with Yonsei Severance Hospital Precision Medicine Center
November
Signed joint research agreement with JW Pharmaceutical for predictive biomarkers
September
Applied for domestic patent of AI-based new drug development system
June
Published proof-of-concept paper on deep learning-based drug development model CDRscan in Scientific Reports 2018
Published validation paper on genetic mutation detection algorithm ADIscan in Nucleic Acids Research 2018
May
Raised KRW 12 billion in Series B funding (Smilegate, KDB Industrial Bank, etc.)
Signed a cooperation agreement with Inha University Hospital for cancer-related medical centers
April
Signed joint research and cooperation MOU with Yuhan Corporation
2017
December
Signed research agreement with CJ Healthcare for discovery of drug active compounds
November
Signed joint research MOU with Yonsei Severance Hospital
August
Registered domestic patent for bio big data analysis method
Published clinical validation paper on NGS testing for rare diseases in Scientific Reports 201
June
Obtained GMP certification from the Ministry of Food and Drug Safety (KTC-CAB-179288)
March
Published validation paper on HLAscan accuracy in BMC Bioinformatics 2017
2016
November
Selected as an Excellent AI Company by the Ministry of Science and ICT
June
Obtained “New Health Technology Certification” for genetic disease screening
Raised KRW 6 billion in Series A funding (Altos Ventures, etc.)
May
Awarded “Outstanding Company” at the Korea Biotechnology Awards
January
Registered as a genetic testing institution with the Korea Disease Control and Prevention Agency
2009-2015
2009-2015

Foundation and Accumulation of Core Technology
2015
November
Obtained approval from the Ministry of Food and Drug Safety to introduce Dx NGS equipment
May
Registered domestic patent for personalized neo-antigen prediction algorithm
February
Completed beta version of PMAP (Personal Genome Map) automatic generation
2014
October
Registered domestic patent for personalized cancer vaccine system
April
Selected as a laboratory company by the Electronics and Telecommunications Research Institute (ETRI)
March
Registered international patent (WO) for anticancer drug response prediction algorithm
2013
December
Selected as one of the “Top 100 Future Technologies and Leaders for 2020”
September
Registered international patent (WO) for genetic mutation-based anticancer drug efficacy prediction
April
Decision to register RVR DBMS/search system with the U.S. Patent and Trademark Office
2012
July
Registered domestic patent for bio big data-based personalized medicine platform
February
Completed genome analysis platform (NGS-pL)
January
Launched integrated genome service for next-generation personalized medicine genome project
2011
December
Registered domestic patent for pharmacogenomics-based anticancer drug response prediction
June
Registered domestic patent for HLA typing method using genome data
2010
August
Registered domestic patent for pharmacogenomics algorithm
2009
October
